{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:02:30Z","timestamp":1787868150738,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Faculty of Medicine Siriraj Hospital, Mahidol University","doi-asserted-by":"publisher","award":["(IO) R016332025"],"award-info":[{"award-number":["(IO) R016332025"]}],"id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019476","name":"Siriraj Foundation","doi-asserted-by":"publisher","award":["D004146"],"award-info":[{"award-number":["D004146"]}],"id":[{"id":"10.13039\/100019476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tenosynovial giant cell tumor (TGCT) is a mesenchymal tumor derived from the synovium of the tendon sheath and joints, most frequently in the large joints. The standard of care for TGCTs is surgical resection. A new targeting approach for treating TGCTs has emerged from studies on the role of the CSF1\/CSF1 receptor (CSF1R) in controlling cell survival and proliferation during the pathogenesis of TGCTs. We established four novel cell lines isolated from the primary tumor tissues of patients with TGCTs. The cell lines were designated Si-TGCT-1, Si-TGCT-2, Si-TGCT-3, and Si-TGCT-4, and the TGCT cells were characterized by CSF1R and CD68. These TGCT cells were then checked for cell proliferation using an MTT assay and three-dimensional spheroid. The responses to pexidartinib (PLX3397) and sotuletinib (BLZ945) were evaluated by two-dimensional MTT assays. All cells were positive for \u03b1\u2011smooth muscle actin (\u03b1\u2011SMA), fibroblast activation protein (FAP), CSF1R, and CD68. Except for Si-TGCT-4, all TGCT cells had high CSF1R expressions. The cells exhibited continuous growth as three-dimensional spheroids formed. Treatment with pexidartinib and sotuletinib inhibited TGCT cell growth and induced cell apoptosis correlated with the CSF1R level. Only Si-TGCT-4 cells demonstrated resistance to the drugs. In addition, the BAX\/BCL-2 ratio increased in cells treated with pexidartinib and sotuletinib. With the four novel TGCT cell lines, we have an excellent model for further in vitro and in vivo studies.<\/jats:p>","DOI":"10.1007\/s13577-022-00823-0","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:52:45Z","timestamp":1669967565000},"page":"456-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis"],"prefix":"10.1007","volume":"36","author":[{"given":"Suyanee","family":"Thongchot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supani","family":"Duangkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasan","family":"Yotchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorranart","family":"Maungsomboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapin","family":"Phimolsarnti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichat","family":"Asavamongkolkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peti","family":"Thuwajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanitra","family":"Thuwajit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9473-8836","authenticated-orcid":false,"given":"Chandhanarat","family":"Chandhanayingyong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"823_CR1","first-page":"2020","volume-title":"Soft Tissue and Bone Tumours","author":"WHO Classification of Tumours","year":"2020","unstructured":"WHO Classification of Tumours. Soft Tissue and Bone Tumours. 5th ed. Lyon: International Agency for Research on Cancer (IARC); 2020. p. 2020.","edition":"5"},{"key":"823_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","volume":"63","author":"EL Staals","year":"2016","unstructured":"Staals EL, Ferrari S, Donati DM, Palmerini E. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. Eur J Cancer. 2016;63:34\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2016.04.022.","journal-title":"Eur J Cancer"},{"issue":"11","key":"823_CR3","doi-asserted-by":"publisher","first-page":"e2000028","DOI":"10.5435\/JAAOSGlobal-D-20-00028","volume":"4","author":"JH Healey","year":"2020","unstructured":"Healey JH, Bernthal NM, van de Sande M. Management of Tenosynovial giant cell tumor: a neoplastic and inflammatory disease. J Am Acad Orthop Surg Glob Res Rev. 2020;4(11):e2000028. https:\/\/doi.org\/10.5435\/JAAOSGlobal-D-20-00028.","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"issue":"7","key":"823_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0046-8177(92)90340-9","volume":"23","author":"FW Abdul-Karim","year":"1992","unstructured":"Abdul-Karim FW, el-Naggar AK, Joyce MJ, Makley JT, Carter JR. Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis. Hum Pathol. 1992;23(7):729\u201335. https:\/\/doi.org\/10.1016\/0046-8177(92)90340-9.","journal-title":"Hum Pathol"},{"issue":"6","key":"823_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","volume":"31","author":"JS Cupp","year":"2007","unstructured":"Cupp JS, Miller MA, Montgomery KD, Nielsen TO, O\u2019Connell JX, Huntsman D, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31(6):970\u20136. https:\/\/doi.org\/10.1097\/PAS.0b013e31802b86f8.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"823_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1073\/pnas.0507321103","volume":"103","author":"RB West","year":"2006","unstructured":"West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3):690\u20135. https:\/\/doi.org\/10.1073\/pnas.0507321103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"823_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/gcc.20501","volume":"47","author":"E Moller","year":"2008","unstructured":"Moller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2008;47(1):21\u20135. https:\/\/doi.org\/10.1002\/gcc.20501.","journal-title":"Genes Chromosomes Cancer"},{"key":"823_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128928","volume":"74","author":"TM Caldwell","year":"2022","unstructured":"Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, et al. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorg Med Chem Lett. 2022;74: 128928. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128928.","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"823_CR9","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","volume":"20","author":"BD Smith","year":"2021","unstructured":"Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, et al. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Mol Cancer Ther. 2021;20(11):2098\u2013109. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0361.","journal-title":"Mol Cancer Ther"},{"key":"823_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820046","volume":"13","author":"M Robert","year":"2022","unstructured":"Robert M, Farese H, Miossec P. Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features. Front Immunol. 2022;13: 820046. https:\/\/doi.org\/10.3389\/fimmu.2022.820046.","journal-title":"Front Immunol"},{"key":"823_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.665442","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Lv J, Zhang H, Xie J, Dai H, Zhang X. Gene expression profiles analyzed using integrating RNA sequencing, and microarray reveals increased inflammatory response, proliferation, and osteoclastogenesis in pigmented villonodular synovitis. Front Immunol. 2021;12: 665442. https:\/\/doi.org\/10.3389\/fimmu.2021.665442.","journal-title":"Front Immunol"},{"issue":"1","key":"823_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","volume":"16","author":"NM Bernthal","year":"2021","unstructured":"Bernthal NM, Spierenburg G, Healey JH, Palmerini E, Bauer S, Group TS, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J Rare Dis. 2021;16(1):191. https:\/\/doi.org\/10.1186\/s13023-021-01820-6.","journal-title":"Orphanet J Rare Dis"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2147\/DDDT.S253232","volume":"14","author":"B Benner","year":"2020","unstructured":"Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, et al. Pexidartinib, a novel small molecule CSF-1R inhibitor in use for Tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development. Drug Des Devel Ther. 2020;14:1693\u2013704. https:\/\/doi.org\/10.2147\/DDDT.S253232.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"823_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","volume":"16","author":"PA Cassier","year":"2015","unstructured":"Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8):949\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(15)00132-1.","journal-title":"Lancet Oncol"},{"issue":"4","key":"823_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-020-01280-5","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Correction to: pexidartinib: first approval. Drugs. 2020;80(4):447. https:\/\/doi.org\/10.1007\/s40265-020-01280-5.","journal-title":"Drugs"},{"issue":"25","key":"823_CR16","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2217\/fon-2020-0307","volume":"16","author":"W Tap","year":"2020","unstructured":"Tap W. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020;16(25):1875\u20138. https:\/\/doi.org\/10.2217\/fon-2020-0307.","journal-title":"Future Oncol"},{"issue":"8","key":"823_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","volume":"52","author":"SH Mun","year":"2020","unstructured":"Mun SH, Park PSU, Park-Min KH. The M-CSF receptor in osteoclasts and beyond. Exp Mol Med. 2020;52(8):1239\u201354. https:\/\/doi.org\/10.1038\/s12276-020-0484-z.","journal-title":"Exp Mol Med"},{"key":"823_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115353","volume":"136","author":"BA Smeester","year":"2020","unstructured":"Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, et al. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone. 2020;136: 115353. https:\/\/doi.org\/10.1016\/j.bone.2020.115353.","journal-title":"Bone"},{"issue":"5","key":"823_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1411366.","journal-title":"N Engl J Med"},{"issue":"13","key":"823_CR20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2217\/fon-2021-1475","volume":"18","author":"C Dharmani","year":"2022","unstructured":"Dharmani C, Wang E, Salas M, McCabe C, Diggs A, Choi Y, et al. Turalio risk evaluation and mitigation strategy for treatment of Tenosynovial giant cell tumor: framework and experience. Future Oncol. 2022;18(13):1595\u2013607. https:\/\/doi.org\/10.2217\/fon-2021-1475.","journal-title":"Future Oncol"},{"issue":"6","key":"823_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2021.8205","volume":"46","author":"S Thongchot","year":"2021","unstructured":"Thongchot S, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Poungvarin N, et al. Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines. Oncol Rep. 2021;46(6):1\u201313.","journal-title":"Oncol Rep"},{"issue":"11","key":"823_CR22","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.27931","volume":"132","author":"A Capes-Davis","year":"2013","unstructured":"Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132(11):2510\u20139. https:\/\/doi.org\/10.1002\/ijc.27931.","journal-title":"Int J Cancer"},{"issue":"6","key":"823_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","volume":"20","author":"MJL Mastboom","year":"2019","unstructured":"Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019;20(6):877\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(19)30100-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"823_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.33312","volume":"127","author":"H Gelderblom","year":"2021","unstructured":"Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2021;127(6):884\u201393. https:\/\/doi.org\/10.1002\/cncr.33312.","journal-title":"Cancer"},{"issue":"10197","key":"823_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(19)30764-0.","journal-title":"Lancet"},{"issue":"2","key":"823_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The Cellosaurus, a Cell-Line Knowledge Resource. J Biomol Tech. 2018;29(2):25\u201338. https:\/\/doi.org\/10.7171\/jbt.18-2902-002.","journal-title":"J Biomol Tech"},{"issue":"1","key":"823_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13577-020-00425-8","volume":"34","author":"R Noguchi","year":"2021","unstructured":"Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, et al. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Hum Cell. 2021;34(1):254\u20139. https:\/\/doi.org\/10.1007\/s13577-020-00425-8.","journal-title":"Hum Cell"},{"issue":"1","key":"823_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1083\/jcb.85.1.153","volume":"85","author":"LJ Guilbert","year":"1980","unstructured":"Guilbert LJ, Stanley ER. Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells. J Cell Biol. 1980;85(1):153\u20139. https:\/\/doi.org\/10.1083\/jcb.85.1.153.","journal-title":"J Cell Biol"},{"issue":"2","key":"823_CR29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.2017.75.8482","volume":"36","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Thomas DM, Tap WD. Locally Aggressive Connective Tissue Tumors. J Clin Oncol. 2018;36(2):202\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.75.8482.","journal-title":"J Clin Oncol"},{"issue":"12","key":"823_CR30","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1002\/ijc.32421","volume":"145","author":"Y Tsuda","year":"2019","unstructured":"Tsuda Y, Hirata M, Katayama K, Motoi T, Matsubara D, Oda Y, et al. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. Int J Cancer. 2019;145(12):3276\u201384. https:\/\/doi.org\/10.1002\/ijc.32421.","journal-title":"Int J Cancer"},{"issue":"1","key":"823_CR31","doi-asserted-by":"publisher","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","volume":"9","author":"FGM Verspoor","year":"2019","unstructured":"Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, et al. Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor. Sci Rep. 2019;9(1):14551. https:\/\/doi.org\/10.1038\/s41598-019-51211-y.","journal-title":"Sci Rep"},{"issue":"1","key":"823_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-3329-3-8","volume":"3","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013;3(1):8. https:\/\/doi.org\/10.1186\/2045-3329-3-8.","journal-title":"Clin Sarcoma Res"},{"key":"823_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","volume":"141","author":"PA Cassier","year":"2020","unstructured":"Cassier PA, Italiano A, Gomez-Roca C, Le Tourneau C, Toulmonde M, D\u2019Angelo SP, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer. 2020;141:162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.038.","journal-title":"Eur J Cancer"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-022-00823-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-022-00823-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-022-00823-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T14:24:35Z","timestamp":1672842275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-022-00823-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s13577-022-00823-0","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"12 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Ethics Committee of Siriraj Hospital, Mahidol University, approved this study\u2019s use of clinical materials. (COA Si 894\/2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication was provided by the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}